Press coverage about Covance (NYSE:CVD) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Covance earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave press coverage about the healthcare company an impact score of 45.8440710277382 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.
Receive News & Ratings for Covance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance Inc. and related companies with MarketBeat.com's FREE daily email newsletter.